Company news
Sophiris Bio Inc news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Sophiris Bio Reports Third Quarter Financial Results and Recent Key Operational Highlights
November 12, 2013
Sophiris Bio Applies for Voluntary Delisting from TSX
November 5, 2013
Sophiris Announces First Patients Dosed in the "PLUS-1" Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia
October 28, 2013
Sophiris Bio to Present at the Stifel Healthcare Conference
September 5, 2013
Sophiris Bio Closes $65 Million Public Offering
August 23, 2013
Sophiris Bio Prices its Previously Announced Public Offering of Common Shares
August 16, 2013
Sophiris Bio Announces Share Consolidation
August 12, 2013
Sophiris Bio Reports Second Quarter Financial Results and Recent Key Operational Highlights
August 5, 2013
Sophiris Bio Announces an Addition to its Board of Directors
July 15, 2013
Sophiris Bio Announces Changes to Board of Directors
July 12, 2013
Sophiris Bio Inc. Announces Election of Directors
June 14, 2013
Sophiris Bio Reports First Quarter Financial Results and Recent Key Operational Highlights
April 30, 2013
Correction - Sophiris Bio Inc. Files Registration Statement for Proposed Initial U.S. Public Offering on the NASDAQ
February 18, 2013
Sophiris Bio Inc. Files Registration Statement for Proposed Initial U.S. Public Offering on the NASDAQ
February 15, 2013
Sophiris Bio Reports Fourth Quarter and Year-End 2012 Financial Results and Key Operational Highlights
February 13, 2013
Sophiris Bio Appoints a New Director to the Board
November 30, 2012
Sophiris Bio Reports Third Quarter Financial Results and Recent Key Operational Highlights
November 12, 2012
Sophiris Bio to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
November 6, 2012
Sophiris Bio Announces 12 Month Follow-Up Data from Phase 2b TRIUMPH Clinical Trial of PRX302 in Patients with Benign Prostatic Hyperplasia
October 9, 2012
Sophiris Bio to Present at the 11th Annual BIO Investor Forum
October 2, 2012
Sophiris Bio Announces Resignation of Alexander Casdin
September 14, 2012
Sophiris' Drug for Benign Prostatic Hyperplasia was Well Tolerated Using the Preferred Transrectal Route of Administration
August 31, 2012
Forty Year Industry Veteran Randall E. Woods Named CEO at Sophiris Bio
August 16, 2012
Sophiris Bio Reports Second Quarter Financial Results
August 13, 2012
Sophiris Bio Reports First Quarter Financial Results and Achievements
May 14, 2012
Protox Therapeutics Changes Name to Sophiris Bio
April 2, 2012